TABLE 1.
Demographic and Clinical Characteristics of Patients Enrolled in the American College of Surgeons Oncology Group Z1071 Trial Who Had Postneoadjuvant Chemotherapy Axillary Ultrasound Images Available (n = 611)
| Characteristic | Value |
|---|---|
|
| |
| Age (y) | |
| Mean ± SD | 50.2 ± 11.0 |
| Median (minimum value, maximum value) | 50 (23, 93) |
| Clinical T category at diagnosis | |
| T0 or Tis | 7 (1.1) |
| T1 | 83 (13.6) |
| T2 | 334 (54.7) |
| T3 | 159 (26.0) |
| T4 | 28 (4.6) |
| Clinical nodal category at presentation | |
| N1 | 579 (94.8) |
| N2 | 32 (5.2) |
| Subtype | |
| ErbB-2a positive | 179 (29.3) |
| Hormone positive and ErbB-2 negative | 276 (45.2) |
| Triple-receptor negative | 156 (25.5) |
| Tumor histologic finding | |
| Invasive ductal carcinoma | 540 (88.4) |
| Invasive lobular carcinoma | 34 (5.6) |
| Mixed | 10 (1.6) |
| Other | 27 (4.4) |
| Clinical assessment of the axilla after chemotherapy | |
| No palpable adenopathy | 512 (83.8) |
| Palpable lymph nodes | 74 (12.1) |
| Fixed or matted lymph nodes | 4 (0.7) |
| Not reported | 21 (3.4) |
Note—Except where otherwise indicated, data are number (%) of patients. Tis = cancers cells are growing in the most superficial layer of tissue but are not growing into deeper tissues.
a
ErbB-2 is also known as HER2/neu.